The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity

[1] Ahima RS(2000)Adipose tissue as an endocrine organ J Clin Endocrinol Metab 11 327-332

[2] Flier JS(2002)Inflammation and atherosclerosis Circulation 105 1135-1143

[3] Libby P(2006)Mechanisms linking obesity with cardiovascular disease Nature 444 875-880

[4] Ridker PM(2005)Visfatin: a protein secreted by visceral fat that mimics the effects of insulin Science 307 426-430

[5] Maseri A(2012)Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology Annu Rev Nutr 32 229-243

[6] Van Gaal LF(2010)Visfatin, glucose metabolism and vascular disease: a review of evidence Diabetol Metab Syndr 2 21-980

[7] Mertens IL(2007)Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization Circulation 115 972-365

[8] De Block CE(2008)Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis Cardiovasc Res 78 356-2704

[9] Fukuhara A(2013)Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity Mol Biol Rep 40 2697-990

[10] Matsuda M(2009)Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents Clin Biochem 42 984-75

[1] Ahima RS(2000)Adipose tissue as an endocrine organ J Clin Endocrinol Metab 11 327-332

[2] Flier JS(2002)Inflammation and atherosclerosis Circulation 105 1135-1143

[3] Libby P(2006)Mechanisms linking obesity with cardiovascular disease Nature 444 875-880

[4] Ridker PM(2005)Visfatin: a protein secreted by visceral fat that mimics the effects of insulin Science 307 426-430

[5] Maseri A(2012)Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology Annu Rev Nutr 32 229-243

[6] Van Gaal LF(2010)Visfatin, glucose metabolism and vascular disease: a review of evidence Diabetol Metab Syndr 2 21-980

[7] Mertens IL(2007)Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization Circulation 115 972-365

[8] De Block CE(2008)Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis Cardiovasc Res 78 356-2704

[9] Fukuhara A(2013)Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity Mol Biol Rep 40 2697-990

[10] Matsuda M(2009)Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents Clin Biochem 42 984-75